2,3,4-tri-O-acetyl-β-D-ribopyranosyl-(1->3)-1,2:4,5-di-O-isopropylidene-β-D-fructopyranose | 918877-21-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 2,3,4-tri-O-acetyl-β-D-ribopyranosyl-(1->3)-1,2:4,5-di-O-isopropylidene-β-D-fructopyranose
• CAS: 918877-21-1
• 化学式: C₂₃H₃₄O₁₃
• 分子量: 518.515
• InChiKey: XXUNSHJUCWCQLZ-ZSJRJLOSSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.55
• 重原子数：
  36.0
• 可旋转键数：
  5.0
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.87
• 拓扑面积：
  143.51
• 氢给体数：
  0.0
• 氢受体数：
  13.0

反应信息

• 作为反应物：
  描述：

  2,3,4-tri-O-acetyl-β-D-ribopyranosyl-(1->3)-1,2:4,5-di-O-isopropylidene-β-D-fructopyranose 在 sodium methylate 、 三氟乙酸 作用下， 以 甲醇 、 二氯甲烷 为溶剂， 反应 7.0h， 生成 (2S,3R,4R,5R)-2-((3S,4R,5R)-2,4-Dihydroxy-2,5-bis-hydroxymethyl-tetrahydro-furan-3-yloxy)-tetrahydro-pyran-3,4,5-triol
  参考文献：
  名称：

  Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives

  摘要：

  A series of novel di and trisaccharide derivatives containing D-fructose moiety at the reducing end have been synthesized and evaluated for their antihyperlipidemic activity in hyperlipidemic hamster model. Among 11 glycosyl fructose derivatives five compounds showed potent antihyperlipidemic activity either by enhancing high-density lipoprotein (HDL) cholesterol concentration and/or lowering triglyceride (TG) level. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.123
• 作为产物：
  描述：

  Acetic acid (3R,4R,5R)-4,5-diacetoxy-2-ethylsulfanyl-tetrahydro-pyran-3-yl ester 、 1,2;4,5-di-O-isopropylidene-β-D-(-)-fructopyranose 在 N-碘代丁二酰亚胺 、 高氯酸 作用下， 以 二氯甲烷 为溶剂， 反应 1.0h， 以78%的产率得到2,3,4-tri-O-acetyl-β-D-ribopyranosyl-(1->3)-1,2:4,5-di-O-isopropylidene-β-D-fructopyranose
  参考文献：
  名称：

  Synthesis and antihyperlipidemic activity of novel glycosyl fructose derivatives

  摘要：

  A series of novel di and trisaccharide derivatives containing D-fructose moiety at the reducing end have been synthesized and evaluated for their antihyperlipidemic activity in hyperlipidemic hamster model. Among 11 glycosyl fructose derivatives five compounds showed potent antihyperlipidemic activity either by enhancing high-density lipoprotein (HDL) cholesterol concentration and/or lowering triglyceride (TG) level. (c) 2006 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2006.08.123